caa a22 4500 606158294 CHVBK 20210128100618.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s10557-015-6625-2 doi (NATIONALLICENCE)springer-10.1007/s10557-015-6625-2 Rationale and Design of Sodium Tanshinone IIA Sulfonate in Left Ventricular Remodeling Secondary to Acute Myocardial Infarction (STAMP-REMODELING) Trial: A Randomized Controlled Study [Elektronische Daten] [Shuai Mao, Xiaotong Li, Lei Wang, Phillip Yang, Minzhou Zhang] Background: Left ventricular (LV) remodeling in ischemic cardiomyopathy is the leading cause of heart failure and is an established prognostic factor for adverse cardiovascular events. Experimental studies suggest that sodium tanshinone IIA sulfonate attenuates cardiac remodeling in animal models of acute myocardial infarction (AMI). However, the effects of this drug in the clinical setting remain unclear. Therefore, the STAMP-REMODELING trial is set up to investigate whether treatment with sodium tanshinone IIA sulfonate would prevent the maladaptive progression to adverse LV remodeling in patients following ST-segment elevation myocardial infarction (STEMI). Methods: Approximately 80 patients with STEMI successfully treated with primary percutaneous coronary intervention (PCI) will be enrolled and randomized to receive sodium tanshinone IIA sulfonate (80mg q.d. for 7days) in addition to standard therapy or the same volume of hydration per day. The primary endpoint is the variation in LV end-diastolic volume index (LVEDVi) assessed with cardiac magnetic resonance imaging (CMR) at baseline and 6months. Conclusion: This study will provide important clinical evidence on the efficacy of sodium tanshinone IIA sulfonate treatment in patients with STEMI when used in combination with current therapies that may significantly reduce adverse LV remodeling and potentially improve clinical outcomes. Trial Registration: Clinical Trials.gov: NCT02524964. Springer Science+Business Media New York, 2015 Left ventricular remodeling nationallicence Sodium tanshinone IIA sulfonate nationallicence Myocardial infarction nationallicence Cardiac magnetic resonance imaging nationallicence ACE : Angiotensin converting enzyme nationallicence AMI : Acute myocardial infarction nationallicence CMR : Cardiovascular magnetic resonance nationallicence EF : Ejection fraction nationallicence LV : Left ventricular nationallicence LVEDV : Left ventricular end-diastolic volume nationallicence LVESV : Left ventricular end-systolic volume nationallicence MACE : Major adverse cardiac event nationallicence MMPs : Matrix metalloproteinases nationallicence NYHA : New York Heart association functional classification nationallicence NSTEACS : Non-ST elevation acute coronary syndrome nationallicence NT-proBNP : N-terminal pro-brain natriuretic peptide nationallicence PCI : Percutaneous coronary intervention nationallicence PMI : Peri-procedural myocardial injury nationallicence SAQ : Seattle Angina Questionnaire nationallicence Mao Shuai Second Clinical Medical College, Guangzhou University of Chinese Medicine, 510405, Guangzhou, China aut Li Xiaotong School of Chemistry & Molecular Biosciences, The University of Queensland, 4072, Brisbane, Australia aut Wang Lei Second Clinical Medical College, Guangzhou University of Chinese Medicine, 510405, Guangzhou, China aut Yang Phillip Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, 94305, Stanford, CA, USA aut Zhang Minzhou Second Clinical Medical College, Guangzhou University of Chinese Medicine, 510405, Guangzhou, China aut Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/6(2015-12-01), 535-542 0920-3206 29:6<535 2015 29 10557 https://doi.org/10.1007/s10557-015-6625-2 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10557-015-6625-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Mao Shuai Second Clinical Medical College, Guangzhou University of Chinese Medicine, 510405, Guangzhou, China aut NATIONALLICENCE 700 1- Li Xiaotong School of Chemistry & Molecular Biosciences, The University of Queensland, 4072, Brisbane, Australia aut NATIONALLICENCE 700 1- Wang Lei Second Clinical Medical College, Guangzhou University of Chinese Medicine, 510405, Guangzhou, China aut NATIONALLICENCE 700 1- Yang Phillip Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, 94305, Stanford, CA, USA aut NATIONALLICENCE 700 1- Zhang Minzhou Second Clinical Medical College, Guangzhou University of Chinese Medicine, 510405, Guangzhou, China aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/6(2015-12-01), 535-542 0920-3206 29:6<535 2015 29 10557